Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1987 1
1998 1
1999 6
2000 6
2001 12
2002 16
2003 7
2004 11
2005 11
2006 13
2007 23
2008 17
2009 21
2010 31
2011 30
2012 39
2013 43
2014 64
2015 97
2016 115
2017 108
2018 114
2019 126
2020 126
2021 140
2022 127
2023 152
2024 158
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,458 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for uni lu
Your search for Zuni Luo retrieved no results
Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.
Hence, the radiopharmaceuticals [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. ...We also provide expert advice, to identify those clinical situations which may justify the off-label use of [( …
Hence, the radiopharmaceuticals [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T are currently being evaluated …
Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Seifert R, et al. PET Clin. 2021 Jul;16(3):391-396. doi: 10.1016/j.cpet.2021.03.004. PET Clin. 2021. PMID: 34053583 Review.
Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. ...
Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter pr …
Inflammatory aspects of Alzheimer's disease.
Botella Lucena P, Heneka MT. Botella Lucena P, et al. Acta Neuropathol. 2024 Aug 28;148(1):31. doi: 10.1007/s00401-024-02790-2. Acta Neuropathol. 2024. PMID: 39196440 Review.
NRAS mutant melanoma: Towards better therapies.
Randic T, Kozar I, Margue C, Utikal J, Kreis S. Randic T, et al. Cancer Treat Rev. 2021 Sep;99:102238. doi: 10.1016/j.ctrv.2021.102238. Epub 2021 May 29. Cancer Treat Rev. 2021. PMID: 34098219 Free article. Review.
The oral-gut microbiome axis in health and disease.
Kunath BJ, De Rudder C, Laczny CC, Letellier E, Wilmes P. Kunath BJ, et al. Nat Rev Microbiol. 2024 Dec;22(12):791-805. doi: 10.1038/s41579-024-01075-5. Epub 2024 Jul 22. Nat Rev Microbiol. 2024. PMID: 39039286 Review.
(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
Rahbar K, Essler M, Eiber M, la Fougère C, Prasad V, Fendler WP, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Pabst KM, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. J Nucl Med. 2023 Dec 1;64(12):1925-1931. doi: 10.2967/jnumed.123.266125. J Nucl Med. 2023. PMID: 37827838 Free PMC article.
The safety and effectiveness of sequential use of (223)Ra and (177)Lu-PSMA in patients with mCRPC are not well described. This study aimed to evaluate (177)Lu-PSMA safety and efficacy in patients with mCRPC previously treated with (223)Ra. ...Median overall survival …
The safety and effectiveness of sequential use of (223)Ra and (177)Lu-PSMA in patients with mCRPC are not well described. This study …
Dose voxel kernel prediction with neural networks for radiation dose estimation.
Götz TI, Lang EW, Schmidkonz C, Kuwert T, Ludwig B. Götz TI, et al. Z Med Phys. 2021 Feb;31(1):23-36. doi: 10.1016/j.zemedi.2020.09.005. Epub 2020 Oct 20. Z Med Phys. 2021. PMID: 33092940 German.
BACKGROUND: Currently there is an ever increasing interest in Lu-177 targeted radionuclide therapies, which target neuro-endocrine and prostate tumours. ...Hence we chose kidneys of 26 patients, who underwent Lu-177-DOTATOC or PSMA therapy, as target organs for our …
BACKGROUND: Currently there is an ever increasing interest in Lu-177 targeted radionuclide therapies, which target neuro-endocrine an …
Galectins at a glance.
Johannes L, Jacob R, Leffler H. Johannes L, et al. J Cell Sci. 2018 May 1;131(9):jcs208884. doi: 10.1242/jcs.208884. J Cell Sci. 2018. PMID: 29717004 Review.
1,458 results